Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth ...Middle East

PR Newswire - News
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech...

    Hence then, the article about viva biotech announces its 2026 interim results ai sparks new paradigm in drug r d cdmo commercial manufacturing accelerates revenue growth was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

    Read More Details
    Finally We wish PressBee provided you with enough information of ( Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth )

    Apple Storegoogle play

    Last updated :

    Also on site :

    Most viewed in News